FindTrial
Sign In

Comparison of topical tretinoin versus topical tazarotene in acne vulgaris.

Comparative efficacy of different concentration of topical tazarotene and topical tretinoin in acne vulgaris. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060308
Enrollment
80
Registered
2023-11-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: Topical tazarotene 0.05%: 20 patients will be given topical tazarotene 0.05% OD at night for a period of 8 weeks, with evaluation at every 2 weeks. Intervention2: Topical tazarotene 0.1

Sponsors

Department of Dermatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of acne vulgaris (Grade 1 & 2) involving face and not requiring systemic therapy. 2. Patients of 18-50 years of age.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating mothers 2. Patients having any systemic illness requiring drugs 3. Patients with signs and symptoms of hyperandrogenism

Design outcomes

Primary

MeasureTime frame
1. To compare the clinical efficacy of topical 0.025% and 0.05% tretinoin with 0.05% and 0.1% tazarotene in acne vulgaris. Timepoint: 2nd, 4th, 6th and 8th week—

Secondary

MeasureTime frame
2. To assess and compare the adverse effects of these therapeutic agents.Timepoint: 2nd, 4th, 6th and 8th week—

Countries

India

Contacts

Public ContactProfessor G P Thami

Government Medical College and Hospital, Chandigarh

thamigp@gmail.com9646121544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026